Acumen Pharmaceuticals, Inc. Research and Development Expense
Acumen Pharmaceuticals, Inc. (ABOS) reported Research and Development Expense of $27.81 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-12
- Acumen Pharmaceuticals, Inc. research and development expense for the quarter ending 2026-06-30 was $27.81M, a 25.09% decline year-over-year.
- Acumen Pharmaceuticals, Inc. research and development expense for the quarter ending 2026-03-31 was $16.48M, a 34.76% decline year-over-year.
- Acumen Pharmaceuticals, Inc. research and development expense for the quarter ending 2025-12-31 was $20.53M, a 40.62% decline year-over-year.
- Acumen Pharmaceuticals, Inc. research and development expense for the quarter ending 2025-09-30 was $21.97M, a 19.37% decline year-over-year.
- Acumen Pharmaceuticals, Inc. research and development expense for fiscal 2025 was $104.89M, a 11.82% increase from fiscal 2024.
- Acumen Pharmaceuticals, Inc. research and development expense for fiscal 2024 was $93.80M, a 121.65% increase from fiscal 2023.
- Acumen Pharmaceuticals, Inc. research and development expense for fiscal 2023 was $42.32M, a 30.77% increase from fiscal 2022.
- Acumen Pharmaceuticals, Inc. research and development expense for fiscal 2022 was $32.36M, a 162.99% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $27.81M 10-Q · filed 2026-08-12 | $44.29M 10-Q · filed 2026-08-12 | $64.82M derived: sum of 3 quarters · filed 2026-08-12 | $86.79M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $16.48M 10-Q · filed 2026-05-12 | $37.01M derived: sum of 2 quarters · filed 2026-05-12 | $58.98M derived: sum of 3 quarters · filed 2026-05-12 | $96.10M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $20.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $42.49M derived: sum of 2 quarters · filed 2026-03-26 | $79.62M derived: sum of 3 quarters · filed 2026-08-12 | $104.89M 10-K · filed 2026-03-26 |
| 2025-09-30 | $21.97M 10-Q · filed 2025-11-12 | $59.09M derived: sum of 2 quarters · filed 2026-08-12 | $84.36M 10-Q · filed 2025-11-12 | $118.93M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $37.13M 10-Q · filed 2026-08-12 | $62.39M 10-Q · filed 2026-08-12 | $96.96M derived: sum of 3 quarters · filed 2026-08-12 | $124.21M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $25.27M 10-Q · filed 2026-05-12 | $59.84M derived: sum of 2 quarters · filed 2026-05-12 | $87.08M derived: sum of 3 quarters · filed 2026-05-12 | $106.61M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $34.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $61.82M derived: sum of 2 quarters · filed 2026-03-26 | $81.35M derived: sum of 3 quarters · filed 2026-03-26 | $93.80M 10-K · filed 2026-03-26 |
| 2024-09-30 | $27.25M 10-Q · filed 2025-11-12 | $46.78M derived: sum of 2 quarters · filed 2025-11-12 | $59.23M 10-Q · filed 2025-11-12 | $72.52M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $19.53M 10-Q · filed 2025-08-12 | $31.98M 10-Q · filed 2025-08-12 | $45.27M derived: sum of 3 quarters · filed 2025-08-12 | $56.45M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $12.45M 10-Q · filed 2025-05-13 | $25.74M derived: sum of 2 quarters · filed 2025-05-13 | $36.92M derived: sum of 3 quarters · filed 2025-05-13 | $46.05M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $13.29M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $24.47M derived: sum of 2 quarters · filed 2025-03-27 | $33.60M derived: sum of 3 quarters · filed 2025-03-27 | $42.32M 10-K · filed 2025-03-27 |
| 2023-09-30 | $11.18M 10-Q · filed 2024-11-12 | $20.31M derived: sum of 2 quarters · filed 2024-11-12 | $29.02M 10-Q · filed 2024-11-12 | $39.77M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $9.13M 10-Q · filed 2024-08-13 | $17.85M 10-Q · filed 2024-08-13 | $28.59M derived: sum of 3 quarters · filed 2024-08-13 | $36.90M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $8.71M 10-Q · filed 2024-05-14 | $19.46M derived: sum of 2 quarters · filed 2024-05-14 | $27.77M derived: sum of 3 quarters · filed 2024-05-14 | $35.09M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $10.75M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $19.05M derived: sum of 2 quarters · filed 2024-03-26 | $26.38M derived: sum of 3 quarters · filed 2024-03-26 | $32.36M 10-K · filed 2024-03-26 |
| 2022-09-30 | $8.31M 10-Q · filed 2023-11-13 | $15.63M derived: sum of 2 quarters · filed 2023-11-13 | $21.61M 10-Q · filed 2023-11-13 | $27.29M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $7.32M 10-Q · filed 2023-08-08 | $13.31M 10-Q · filed 2023-08-08 | $18.98M derived: sum of 3 quarters · filed 2023-08-08 | $20.78M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $5.99M 10-Q · filed 2023-05-09 | $11.66M derived: sum of 2 quarters · filed 2023-05-09 | $13.46M derived: sum of 3 quarters · filed 2023-05-09 | $15.71M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $5.67M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | $7.47M derived: sum of 2 quarters · filed 2023-03-27 | $9.73M derived: sum of 3 quarters · filed 2023-03-27 | $12.30M 10-K · filed 2023-03-27 |
| 2021-09-30 | $1.80M 10-Q · filed 2022-11-14 | $4.05M derived: sum of 2 quarters · filed 2022-11-14 | $6.63M 10-Q · filed 2022-11-14 | $7.66M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $2.25M 10-Q · filed 2022-08-15 | $4.83M 10-Q · filed 2022-08-15 | $5.86M derived: sum of 3 quarters · filed 2022-08-15 | $8.85M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $2.58M 10-Q · filed 2022-05-16 | $3.60M derived: sum of 2 quarters · filed 2022-05-16 | $6.60M derived: sum of 3 quarters · filed 2022-05-16 | $8.53M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $1.03M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $4.02M derived: sum of 2 quarters · filed 2022-03-28 | $5.95M derived: sum of 3 quarters · filed 2022-03-28 | $8.00M 10-K · filed 2022-03-28 |
| 2020-09-30 | $2.99M 10-Q · filed 2021-11-15 | $4.92M derived: sum of 2 quarters · filed 2021-11-15 | $6.97M 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $1.93M 10-Q · filed 2021-08-16 | $3.98M 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |